Navigation Links
ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR

LOS ANGELES--(BUSINESS WIRE)--Apr 16, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) presented preclinical data yesterday on indibulin (ZIO-301) at the American Association of Cancer Research (AACR) meeting in Los Angeles. These data demonstrate that indibulin has distinct biologic and molecular properties from other tubulin binding agents and strongly suggest a very different toxicity profile, particularly with regard to peripheral neuropathy. While indibulin binds to tubulin in general, it does not bind to neuronal specific tubulin and does not disrupt normal axonal microtubules in vitro, likely accounting for the difference with regard to neurotoxicity.

Indibulin is one of a class of cancer therapeutics that includes the taxanes (paclitaxel and docetaxel) and Vinca alkaloids, some of the most widely used anti-cancer agents in the world today. In spite of their effectiveness, all of the commercially available agents exhibit some degree of neurotoxicity that in many cases can be dose limiting.

Indibulin, like the taxanes and vinca alkaloids, interferes with the function of microtubules by binding to their building blocks, tubulin. However, the specific tubulin binding site for indibulin is different from that of taxanes and Vinca alkaloids. The observed lack of neurotoxicity in animals receiving indibulin treatment is thought to be related to this difference in binding site, and in particular to the observation that indibulin does not bind to neuronal-specific tubulin. Indibulin is active across a diverse range of human, mouse, and rat tumor cell lines in vitro and in human tumor xenografts, including glioblastoma and in drug-resistant tumor cell lines.

"We are very excited about indibulin's potential," commented Brian Schwartz, M.D., Chief Medical Officer at ZIOPHARM. "The fact that it is orally available and shows no signs of the neurotoxicity in preclinical models associated with other agents i n this class is particularly intriguing. If no neurotoxicity is seen in ongoing clinical trials, indibulin will clearly distinguish itself from other marketed agents in this class."

About ZIO-301

ZIO-301 (indibulin) is a novel synthetic anti-mitotic agent that binds to tubulin, destabilizes microtubulin polymerization, and arrests tumor cell growth at the G2/M phase. Microtubulins are well-established targets for anti-cancer drug development and tubulin-binding drugs such as taxanes and Vinca alkaloids are currently widely used to treat cancer. Indibulin is in a phase I dose-ranging and safety study in Europe. The Company expects to begin phase I/II trials in the U.S. soon.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risk s that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.



ZIOPHARM Oncology, Inc.
Suzanne McKenna, 646-214-0703
Tina Posterli, 917-322-2565


Related medicine technology :

1. ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR
3. ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
4. ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. announced ... a Healthcare IT consulting, development and support company. The purchase will expand the ... within DataTrade to extend the services currently provided by Healthjump. , ...
(Date:11/30/2015)... Maryland (PRWEB) , ... November 30, 2015 , ... ... interactions could be of critical importance to the medical schools of the future. ... exhibited its healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized by ...
(Date:11/30/2015)... ... 30, 2015 , ... TransPack Volume 6 features 30 customizable transitions created exclusively ... transitions to wipes with blur & drop shadow options. Utilize the controls in ... one clip to the next with TransPack's easily customizable styles. , TransPack ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... worldwide today released the results of a survey of educational needs for pharmacists ... found a growing global demand for high quality online and face-to-face education for ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... to announce their strategic partnership at the Radiological Society of North America ... Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, announced their ...
Breaking Medicine News(10 mins):